Antibiotic sensitivity culture the bacteria. This can help in the diagnosis. Once a culture is established, there are two possible ways to get an antibiogram: Once the MIC is calculated, it can be compared to known values for a given bacterium and antibiotic: e.g. a MIC > 0,06 µg/ml may be interpreted as a penicillin-resistant "Streptococcus pneumoniae". Such information may be useful to the clinician, who can change the empirical treatment, to a more custom-tailored treatment that is directed only at the causative bacterium. Often clinical specimens are sent to the clinical laboratory for culture and sensitivity (C&S), which is culture and
Antibiotic and antifungals treating life-threatening infections based on smaller clinical trials. The CDC will monitor the use of antibiotics and the emerging resistance, and publish the data. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms' or 'breakpoints', will provide accurate data to healthcare professionals. According to Allan Coukell, senior director for health programs at The Pew Charitable Trusts, "By allowing drug developers to rely on smaller datasets, and clarifying FDA's authority to tolerate a higher level of uncertainty for these drugs when making a risk/benefit calculation, ADAPT would make the clinical trials more feasible." Antibiotic An antibiotic